35 related articles for article (PubMed ID: 34655330)
1. Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth.
Zhao Y; Tu MJ; Yu YF; Wang WP; Chen QX; Qiu JX; Yu AX; Yu AM
Biochem Pharmacol; 2015 Dec; 98(4):602-13. PubMed ID: 26518752
[TBL] [Abstract][Full Text] [Related]
2. Expression of the miR-150 tumor suppressor is restored by and synergizes with rapamycin in a human leukemia T-cell line.
Podshivalova K; Wang EA; Hart T; Salomon DR
Leuk Res; 2018 Nov; 74():1-9. PubMed ID: 30269036
[TBL] [Abstract][Full Text] [Related]
3. Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment.
Zarone MR; Misso G; Grimaldi A; Zappavigna S; Russo M; Amler E; Di Martino MT; Amodio N; Tagliaferri P; Tassone P; Caraglia M
Sci Rep; 2017 Dec; 7(1):17949. PubMed ID: 29263373
[TBL] [Abstract][Full Text] [Related]
4. Altering β-cell number through stable alteration of miR-21 and miR-34a expression.
Backe MB; Novotny GW; Christensen DP; Grunnet LG; Mandrup-Poulsen T
Islets; 2014; 6(1):e27754. PubMed ID: 25483877
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a set of tumor suppressor microRNAs in T cell acute lymphoblastic leukemia.
Sanghvi VR; Mavrakis KJ; Van der Meulen J; Boice M; Wolfe AL; Carty M; Mohan P; Rondou P; Socci ND; Benoit Y; Taghon T; Van Vlierberghe P; Leslie CS; Speleman F; Wendel HG
Sci Signal; 2014 Nov; 7(352):ra111. PubMed ID: 25406379
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous microRNA-612 restoration and 5-FU treatment inhibit the growth and migration of human PANC-1 pancreatic cancer cells.
Javadrashid D; Mohammadzadeh R; Baghbanzadeh A; Safaee S; Amini M; Lotfi Z; Baghbani E; Khaze Shahgoli V; Baradaran B
EXCLI J; 2021; 20():160-173. PubMed ID: 33564285
[TBL] [Abstract][Full Text] [Related]
7. Regulatory network analysis reveals the oncogenesis roles of feed-forward loops and therapeutic target in T-cell acute lymphoblastic leukemia.
Xia M; Zhang Q; Luo M; Li P; Wang Y; Lei Q; Guo AY
BMC Med Genomics; 2019 Jan; 12(1):8. PubMed ID: 30646895
[TBL] [Abstract][Full Text] [Related]
8. The impact of oleuropein on miRNAs regulating cell death signaling pathway in human cervical cancer cells.
Amini-Farsani Z; Hashemi Sheikhshabani S; Shaygan N; Asgharzade S
Biotechnol Appl Biochem; 2024 Feb; 71(1):61-71. PubMed ID: 37849224
[TBL] [Abstract][Full Text] [Related]
9. A High-Throughput Small Molecule Screen Identifies Ouabain as Synergistic with miR-34a in Killing Lung Cancer Cells.
Rupaimoole R; Yoon B; Zhang WC; Adams BD; Slack FJ
iScience; 2020 Feb; 23(2):100878. PubMed ID: 32062455
[TBL] [Abstract][Full Text] [Related]
10. The Effect of the Persian Gulf Jellyfish (Cassiopea andromeda) Venom on the Expression of P15, P21, P53, DNMT1, and Bcl-2 in Acute Lymphoblastic Leukemia Jurkat Cells.
Dehghani R; Amrooni A; Hosseinpour-Soleimani F; Mohebbi G; Obeidi N
Int J Hematol Oncol Stem Cell Res; 2023 Jul; 17(3):177-185. PubMed ID: 37817966
[No Abstract] [Full Text] [Related]
11. Synthetic miR-34a against solid tumours: a predictable failure.
Mockly S; Seitz H
Br J Cancer; 2023 Feb; 128(3):478-480. PubMed ID: 36550206
[TBL] [Abstract][Full Text] [Related]
12. A novel nanoprobe for visually investigating the controversial role of miRNA-34a as an oncogene or tumor suppressor in cancer cells.
Chen Z; Ge C; Zhu X; Sun P; Sun Z; Derkach T; Zhou M; Wang Y; Luan M
Anal Methods; 2024 Feb; 16(5):667-675. PubMed ID: 38230518
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma.
Huang YH; Wan CL; Dai HP; Xue SL
Ann Hematol; 2023 Aug; 102(8):2001-2013. PubMed ID: 37227492
[TBL] [Abstract][Full Text] [Related]
14. Implication of microRNAs in Carcinogenesis with Emphasis on Hematological Malignancies and Clinical Translation.
Gaál Z
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628648
[TBL] [Abstract][Full Text] [Related]
15. miRNAs in Lymphocytic Leukaemias-The miRror of Drug Resistance.
Sbirkov Y; Vergov B; Mehterov N; Sarafian V
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563051
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with miR-34a and doxorubicin synergistically induced apoptosis in T-cell acute lymphoblastic leukemia cell line.
Najjary S; Mohammadzadeh R; Mansoori B; Vahidian F; Mohammadi A; Doustvandi MA; Khaze V; Hajiasgharzadeh K; Baradaran B
Med Oncol; 2021 Oct; 38(12):142. PubMed ID: 34655330
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Forkhead box protein M1 by thiostrepton increases chemosensitivity to doxorubicin in T-cell acute lymphoblastic leukemia.
Wang JY; Jia XH; Xing HY; Li YJ; Fan WW; Li N; Xie SY
Mol Med Rep; 2015 Jul; 12(1):1457-64. PubMed ID: 25760224
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-101 regulates T-cell acute lymphoblastic leukemia progression and chemotherapeutic sensitivity by targeting Notch1.
Qian L; Zhang W; Lei B; He A; Ye L; Li X; Dong X
Oncol Rep; 2016 Nov; 36(5):2511-2516. PubMed ID: 27666896
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of PEBP4, a target of miR-34a, sensitizes drug-resistant lung cancer cells.
Yu G; Zhong N; Chen G; Huang B; Wu S
Tumour Biol; 2014 Oct; 35(10):10341-9. PubMed ID: 25038915
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
